Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Averett

Showing results (221-230 of 304) with videos related to

Pageof 31
Sort By:
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Scientific Reports|March 28, 2014
Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancerMichael J McGuire, Bethany Powell Gray, Shunzi Li, et al.
Oncotarget|March 28, 2018
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerDaniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2015
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal TransitionMilena P Mak, Pan Tong, Lixia Diao, et al.
Nanotechnology|February 20, 2015
Morphology dependent field emission of acid-spun carbon nanotube fibersS B Fairchild, J Boeckl, T C Back, et al.
Plos One|February 21, 2012
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parametersYong He, Zhen Zhou, Wayne L Hofstetter, et al.
Cancer Research|May 12, 2017
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or OlaparibTriparna Sen, Pan Tong, C Allison Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized StudyLauren Averett Byers, Dmitry Bentsion, Steven Gans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2021
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III StudySuresh S Ramalingam, Silvia Novello, Salih Zeki Guclu, et al.
Nature Reviews. Cancer|June 9, 2019
Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model dataCharles M Rudin, John T Poirier, Lauren Averett Byers, et al.
Pageof 31

Showing results (221-230 of 304) with videos related to

Sort By:
Pageof 31
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Scientific Reports|March 28, 2014
Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancerMichael J McGuire, Bethany Powell Gray, Shunzi Li, et al.
Oncotarget|March 28, 2018
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerDaniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2015
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal TransitionMilena P Mak, Pan Tong, Lixia Diao, et al.
Nanotechnology|February 20, 2015
Morphology dependent field emission of acid-spun carbon nanotube fibersS B Fairchild, J Boeckl, T C Back, et al.
Plos One|February 21, 2012
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parametersYong He, Zhen Zhou, Wayne L Hofstetter, et al.
Cancer Research|May 12, 2017
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or OlaparibTriparna Sen, Pan Tong, C Allison Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized StudyLauren Averett Byers, Dmitry Bentsion, Steven Gans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2021
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III StudySuresh S Ramalingam, Silvia Novello, Salih Zeki Guclu, et al.
Nature Reviews. Cancer|June 9, 2019
Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model dataCharles M Rudin, John T Poirier, Lauren Averett Byers, et al.
Pageof 31